Artificial Oxygen Carriers - The New Doping Threat in Endurance Sport?
暂无分享,去创建一个
[1] H. Northoff,et al. A SYSTEM ESTABLISHING COMPATIBILITY PROFILES FOR ARTIFICIAL OXYGEN CARRIERS AND OTHER SUBSTANCES , 2001 .
[2] David T. Martin,et al. Reticulocyte parameters as potential discriminators of recombinant human erythropoietin abuse in elite athletes. , 2000, International journal of sports medicine.
[3] D. Spahn,et al. Eliminating Blood Transfusions: New Aspects and Perspectives , 2000, Anesthesiology.
[4] A. Greenburg,et al. A phase I study of oxidized raffinose cross-linked human hemoglobin , 2000, Critical care medicine.
[5] F. Lasne,et al. Recombinant erythropoietin in urine , 2000, Nature.
[6] J. Berridge,et al. Randomized Trial of Diaspirin Cross-linked Hemoglobin Solution as an Alternative to Blood Transfusion after Cardiac Surgery , 2000, Anesthesiology.
[7] P. Buehler,et al. Purification and chemical modifications of hemoglobin in developing hemoglobin based oxygen carriers. , 2000, Advanced drug delivery reviews.
[8] D. Spahn,et al. Current status of artificial oxygen carriers. , 2000, Advanced drug delivery reviews.
[9] A. Gulati,et al. Current aspects in pharmacology of modified hemoglobins. , 2000, Advanced drug delivery reviews.
[10] O. Habler,et al. Tissue perfusion and oxygenation with blood substitutes. , 2000, Advanced drug delivery reviews.
[11] L. V. von Segesser,et al. Blood Profile during and after Hemoglobin Substitute Administration , 2000, The International journal of artificial organs.
[12] D. Gens,et al. Diaspirin Cross-Linked Hemoglobin (DCLHb) in the Treatment of Severe Traumatic Hemorrhagic Shock: A Randomized Controlled Efficacy Trial , 1999 .
[13] F. Bressolle,et al. Effects of erythropoietin administration in training athletes and possible indirect detection in doping control. , 1999, Medicine and science in sports and exercise.
[14] A. Burlingame,et al. Structural characterization of human hemoglobin crosslinked by bis(3,5‐dibromosalicyl) fumarate using mass spectrometric techniques , 1997, Protein science : a publication of the Protein Society.
[15] W. Sibbald,et al. Diaspirin crosslinked hemoglobin improves systemic oxygen uptake in oxygen supply-dependent septic rats. , 1997, American journal of respiratory and critical care medicine.
[16] D. Bailey,et al. Physiological implications of altitude training for endurance performance at sea level: a review. , 1997, British journal of sports medicine.
[17] M. Wolfson,et al. Analysis of perfluorochemical elimination from the respiratory system. , 1997, Journal of applied physiology.
[18] K. Messmer,et al. Effects of diaspirin-cross-linked hemoglobin (DCLHb) on local tissue oxygen tension in striated skin muscle: an efficacy study in the hamster. , 1997, The Journal of laboratory and clinical medicine.
[19] D. Callas,et al. In vitro effects of a novel hemoglobin-based oxygen carrier on routine chemistry, therapeutic drug, coagulation, hematology, and blood bank assays. , 1997, Clinical chemistry.
[20] A. Bodenham,et al. Initial evaluation of diaspirin cross-linked hemoglobin (DCLHb) as a vasopressor in critically ill patients. , 1997, Critical care medicine.
[21] E. Kochs,et al. Haemodynamic changes and skeletal muscle oxygen tension during complete blood exchange with ultrapurified polymerized bovine haemoglobin , 1997, Intensive Care Medicine.
[22] B D Levine,et al. "Living high-training low": effect of moderate-altitude acclimatization with low-altitude training on performance. , 1997, Journal of applied physiology.
[23] J. Schulte am Esch,et al. Bovine hemoglobin increases skeletal muscle oxygenation during 95% artificial arterial stenosis. , 1997, Surgery.
[24] C. Otto,et al. Initial experience with partial liquid ventilation in adult patients with the acute respiratory distress syndrome. , 1996, JAMA.
[25] W. Colburn,et al. Phase I study of the safety and pharmacologic effects of diaspirin cross-linked hemoglobin solution. , 1996, Critical care medicine.
[26] M. Sawka,et al. American College of Sports Medicine position stand. The use of blood doping as an ergogenic aid. , 1996, Medicine and science in sports and exercise.
[27] G. S. Hughes,et al. Hemoglobin‐based oxygen carrier preserves submaximal exercise capacity in humans , 1995, Clinical pharmacology and therapeutics.
[28] RUTH E. Benesch,et al. Hemoglobin tetramers stabilized by a single intramolecular cross-link , 1991, Journal of protein chemistry.
[29] B. Ekblom,et al. Effect of erythropoietin administration on mammal aerobic power , 1991 .
[30] W. Odling‐Smee. ABC of transfusion. Red cell substitutes. , 1990, BMJ.
[31] B. Berglund,et al. Effect of reinfusion of autologous blood on exercise performance in cross-country skiers. , 1987, International journal of sports medicine.
[32] J. Lafortune,et al. Renal vascular effects of stroma and stroma-free hemoglobin. , 1979, Surgical forum.
[33] B. Ekblom,et al. Response to exercise after blood loss and reinfusion. , 1972, Journal of applied physiology.
[34] B. Saltin,et al. Maximal oxygen uptake in athletes. , 1967, Journal of applied physiology.
[35] R. Winslow. Safety and utility of blood substitutes. , 2000, Developments in Biologicals.
[36] P. Keipert,et al. Randomized safety studies of intravenous perflubron emulsion. II. Effects on immune function in healthy volunteers. , 2000, Anesthesia and analgesia.
[37] C J Gore,et al. A novel method utilising markers of altered erythropoiesis for the detection of recombinant human erythropoietin abuse in athletes. , 2000, Haematologica.
[38] R. Winslow. New transfusion strategies: red cell substitutes. , 1999, Annual review of medicine.
[39] M. Lamy,et al. Red blood cell substitutes: fluorocarbon emulsions and haemoglobin solutions. , 1999, British medical bulletin.
[40] J. Baron. Haemoglobin therapy in clinical practice: use and characteristics of DCLHb. , 1998, British journal of anaesthesia.
[41] R. Winslow,et al. Fluid resuscitation with O2 vs. non-O2 carriers after 2 h of hemorrhagic shock in conscious hamsters. , 1997, The American journal of physiology.
[42] J. Hess. Blood substitutes. , 1996, Seminars in hematology.
[43] P. Keipert. Use of Oxygent, a perfluorochemical-based oxygen carrier, as an alternative to intraoperative blood transfusion. , 1995, Artificial cells, blood substitutes, and immobilization biotechnology.
[44] G. Evans,et al. Initial clinical experience with a rationally designed, genetically engineered recombinant human hemoglobin. , 1994, Artificial cells, blood substitutes, and immobilization biotechnology.
[45] S. Flaim. Pharmacokinetics and side effects of perfluorocarbon-based blood substitutes. , 1994, Artificial cells, blood substitutes, and immobilization biotechnology.
[46] N. Afonin,et al. The elimination peculiarities of perfluorocarbon emulsions stabilized with egg yolk phospholipid. , 1994, Artificial cells, blood substitutes, and immobilization biotechnology.
[47] D. L. Parsons,et al. Perfluorochemical erythrocyte substitutes: disposition and effects on drug distribution and elimination. , 1991, Drug metabolism reviews.